Quick Answer
Jade Biosciences, Inc. reported Earnings Per Share Diluted of $3.19 (loss) per share for the year ending 2025.
- Jade Biosciences, Inc. showed a decrease of -30.7% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Jade Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $0.26 (loss) per share | Q1 2022: $0.45 (loss) per share | Q2 2022: $0.49 (loss) per share | Q3 2022: $0.56 (loss) per share | Q1 2023: $0.67 (loss) per share | Q2 2023: $0.76 (loss) per share | Q3 2023: $0.71 (loss) per share | Q1 2024: $0.83 (loss) per share | Q2 2024: $0.86 (loss) per share | Q2 2024: $0.19 (loss) per share | Q3 2024: $5.16 (loss) per share | Q1 2025: $0.09 (loss) per share | Q2 2025: $0.86 (loss) per share | Q3 2025: $0.48 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Jade Biosciences, Inc.'s Earnings Per Share Diluted has declined by 70.6%.
- Historical annual values: Fiscal year 2025: $3.19 (loss) per share | Fiscal year 2024: $2.44 (loss) per share | Fiscal year 2023: $2.87 (loss) per share | Fiscal year 2022: $2.10 (loss) per share | Fiscal year 2021: $1.87 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: